Roanna Ruiz
Stock Analyst at Leerink Partners
(0.60)
# 2,980
Out of 4,479 analysts
51
Total ratings
21.21%
Success rate
-28.28%
Average return
Main Sectors:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Initiates: Outperform | $8 | $2.45 | +226.53% | 1 | May 10, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $7.57 | +84.94% | 1 | Apr 5, 2024 | |
| SPRY ARS Pharmaceuticals | Upgrades: Outperform | $6 → $18 | $8.73 | +106.19% | 2 | Mar 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $319.01 | +3.45% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $54.70 | +6.03% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $32.67 | -23.48% | 1 | Apr 11, 2023 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Perform | $49 | $13.07 | +274.90% | 10 | Feb 9, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $5 | $2.17 | +130.41% | 4 | Jan 27, 2023 | |
| VIR Vir Biotechnology | Maintains: Outperform | $45 → $43 | $9.10 | +372.53% | 3 | Jan 27, 2023 | |
| SCPH scPharmaceuticals | Maintains: Outperform | $12 → $13 | $4.32 | +200.93% | 5 | Jan 27, 2023 | |
| AVIR Atea Pharmaceuticals | Maintains: Market Perform | $8 → $6 | $3.37 | +78.04% | 6 | Jan 27, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Outperform | $19 | $20.58 | -7.68% | 1 | Dec 20, 2022 | |
| LNTH Lantheus Holdings | Maintains: Outperform | $110 → $120 | $80.00 | +50.00% | 3 | Nov 15, 2022 | |
| ALGS Aligos Therapeutics | Maintains: Market Perform | $3 → $2 | $0.37 | +442.01% | 7 | Nov 3, 2022 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $3 → $2 | $0.69 | +191.55% | 5 | Oct 19, 2022 |
Aquestive Therapeutics
May 10, 2024
Initiates: Outperform
Price Target: $8
Current: $2.45
Upside: +226.53%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $7.57
Upside: +84.94%
ARS Pharmaceuticals
Mar 5, 2024
Upgrades: Outperform
Price Target: $6 → $18
Current: $8.73
Upside: +106.19%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $319.01
Upside: +3.45%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $54.70
Upside: +6.03%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $32.67
Upside: -23.48%
Enanta Pharmaceuticals
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.07
Upside: +274.90%
Xeris Biopharma Holdings
Jan 27, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $2.17
Upside: +130.41%
Vir Biotechnology
Jan 27, 2023
Maintains: Outperform
Price Target: $45 → $43
Current: $9.10
Upside: +372.53%
scPharmaceuticals
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $4.32
Upside: +200.93%
Atea Pharmaceuticals
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.37
Upside: +78.04%
NewAmsterdam Pharma Company
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $20.58
Upside: -7.68%
Lantheus Holdings
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $80.00
Upside: +50.00%
Aligos Therapeutics
Nov 3, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.37
Upside: +442.01%
Amarin Corporation
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.69
Upside: +191.55%